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Cellular/Molecular
COX-2-Derived Prostaglandin E2 Produced by Pyramidal
Neurons Contributes to Neurovascular Coupling in the
Rodent Cerebral Cortex
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Vasodilatory prostaglandins play a key role in neurovascular coupling (NVC), the tight link between neuronal activity and local cerebral
blood flow, but their precise identity, cellular origin and the receptors involved remainunclear.Herewe show in rats thatNMDA-induced
vasodilationandhemodynamic responses evokedbywhisker stimulation involve cyclooxygenase-2 (COX-2) activity andactivationof the
prostaglandin E2 (PgE2) receptors EP2 and EP4. Using liquid chromatography-electrospray ionization-tandemmass spectrometry, we
demonstrate thatPgE2 is releasedbyNMDAin cortical slices. The characterizationofPgE2producing cells by immunohistochemistry and
single-cell reverse transcriptase-PCR revealed that pyramidal cells and not astrocytes are themain cell type equipped for PgE2 synthesis,
one third expressing COX-2 systematically associatedwith a PgE2 synthase. Consistent with their central role in NVC, in vivo optogenetic
stimulation of pyramidal cells evoked COX-2-dependent hyperemic responses in mice. These observations identify PgE2 as the main
prostaglandinmediating sensory-evokedNVC, pyramidal cells as their principal source and vasodilatory EP2 and EP4 receptors as their
targets.
Key words: astrocytes; cerebral cortex; cyclooxygenase-2; interneurons; pyramidal cells
Introduction
Neurovascular coupling (NVC), the tight link between neuronal
activity and local cerebral blood flow, is essential for normal brain
function. It is also the physiological basis of functional brain
imaging techniques, such as positron emission tomography and
functional magnetic resonance imaging that are widely used to
map neuronal activity using hemodynamic signals (Fox et al.,
1988; Logothetis et al., 2001; Iadecola, 2004; Lauritzen, 2005). In
several pathologies including Alzheimer’s disease and stroke,
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Significance Statement
Brain function critically depends on a permanent spatiotemporal match between neuronal activity and blood supply, known as
NVC. In the cerebral cortex, prostaglandins are major contributors to NVC. However, their biochemical identity remains elusive
and their cellular origins are still under debate. Although astrocytes can induce vasodilations through the release of prostaglan-
dins, the recruitment of this pathway during sensory stimulation is questioned. Usingmultidisciplinary approaches from single-
cell reverse transcriptase-PCR,mass spectrometry, to ex vivo and in vivo pharmacology and optogenetics, we provide compelling
evidence identifyingPgE2 as themainprostaglandin inNVC, pyramidal neurons as theirmain cellular source and the vasodilatory
EP2 and EP4 receptors as their main targets. These original findings will certainly change the current view of NVC.
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NVC is altered by dysfunction in the neuronal, astroglial, and/or
vascular compartments of the neurovascular unit (Iadecola,
2004; Zlokovic, 2011).
Despite this physiopathological importance the cellular and
molecular mechanisms of NVC remain elusive. In the neocortex
they involve various messengers (Attwell et al., 2010; Cauli and
Hamel, 2010; Leithner et al., 2010; Liu et al., 2012). In rodents,
vasodilatory prostaglandins play a key role in NVC accounting
for approximately one-half of the hyperemic response to sensory
stimuli (Niwa et al., 2000; Bakalova et al., 2002; Stefanovic et al.,
2006; Lecrux et al., 2011). Prostaglandins are arachidonic acid
derivatives produced by the sequential action of rate-limiting
cyclooxygenases (COXs) and terminal synthesizing enzymes
specifying their nature (Funk, 2001). Presumably because of the
lack of selective inhibitors for terminal enzymes, most studies
relied only on inhibiting COX-1 and/or COX-2 activity (Niwa et
al., 2000, 2001; Bakalova et al., 2002; Zonta et al., 2003; Stefanovic
et al., 2006; Takano et al., 2006; Gordon et al., 2008; Lecrux et al.,
2011), hence lacking determination of the prostaglandin subspe-
cies relevant for NVC.
In the cerebral cortex prostaglandin E2 (PgE2) and prostacy-
clin (PgI2) are the main prostaglandins relaxing vascular smooth
muscle cells and pericytes through activation of EP2, EP4, or IP
receptors (Davis et al., 2004; Maubach et al., 2009; Myren et al.,
2010, 2011; Woodward et al., 2011; Hall et al., 2014). Although
antagonism of these receptors provides a means to identify the
NVC prostaglandins, their use is still poorly documented (Hall et
al., 2014) and has been limited by the confounding constrictive
effect of the PgE2 receptor EP1 (Dabertrand et al., 2013).
The cellular sources of the NVC prostaglandins are also un-
certain since different synthesizing enzymes are expressed in var-
ious cell types including neurons, astrocytes, microglia, and
endothelial cells (Yamagata et al., 1993; Breder et al., 1995; Kauf-
mann et al., 1996; Mehl et al., 1999; Vazquez-Tello et al., 2004;
Wang et al., 2005; Cahoy et al., 2008; Anrather et al., 2011; Lecrux
et al., 2011).
We addressed these issues using ex vivo and in vivo approaches,
and found that COX-2 and the PgE2 receptors EP2 and EP4 are
essential contributors ofNVCresponses in the cerebral cortex.Con-
sistently we demonstrate the PgE2 release ex vivo bymeans of liquid
chromatography-electrospray ionization-tandem mass spectrome-
try (LC-ESI-MS/MS). Using immunocytochemistry and single-cell
reverse transcriptase-PCR (scRT-PCR), we established that pyrami-
dal cells are the major cell type equipped for COX-2-derived PgE2
synthesis.We further demonstrated their central role by concurrent
in vivo optogenetic photostimulation of pyramidal cells and phar-
macologicalmanipulationsof theNVCresponse.Our findings iden-
tify pyramidal cells and PgE2, respectively, as the major source and
key vasoactive messenger of NVC responses to sensory stimulation.
Materials andMethods
Animals. Wistar rats (postnatal days 17.0  0.1; Janvier) were used for
patch-clamp recordings, vascular reactivity and measurement of prosta-
noids in acute slices. Adult Wistar or Sprague-Dawley rats (250–300 g)
were respectively used for immunostaining (n 7) or whisker-induced
NVC experiments (n  15). The Jackson Laboratory Line B6;129P-
Emx1tm1Jlr/J (Gorski et al., 2002) mice were crossed with B6;129S-
Gt(ROSA)26Sortm32.1(CAG-COP4*H134R/EYFP)Hze/J mice (Madisen et al.,
2012). Five male and female 2- to 4-month-old animals from the resul-
tant strain weighing 20–30 g were used for optogenetic experiments.
B6.Cg-Tg(Thy1-YFPH)2Jrs/J mice (Feng et al., 2000) of the same age and
weight were used for controls (n  4). All animals were housed in a
temperature-controlled (21–25°C) room under daylight conditions and
were given water ad libitum. A maximum of five mice or three rats are
housed per cage and single animal housing was avoided. All experiments
were performed in accordance with the EUCouncil Directive 86-609, the
British Columbia Animal Care Committee and animal and Ethics com-
mittee of the Montreal Neurological Institute in accordance with Cana-
dian Council for Animal Care guidelines.
Slice preparation. After decapitation brains were quickly removed and
placed into cold (4°C) oxygenated artificial CSF (aCSF) containing the
following (in mM): 126 NaCl, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2,
26 NaHCO3, 10 glucose, 15 sucrose, and 1 kynurenic acid (Sigma-
Aldrich). For patch-clamp recordings and vascular reactivity rat coronal
slices (300 m thick) containing the barrel cortex were cut with a vi-
bratome (VT1000S; Leica) and allowed to recover at room temperature
for at least 1 h in aCSF saturated with O2/CO2 (95%/5%) as previously
described (Karagiannis et al., 2009). Slices were then transferred to a
submerged recording chamber and perfused with oxygenated aCSF lack-
ing kynurenic acid. Blood vessels and cells were first visualized in the slice
under infrared (IR) illumination, using 60 (LUMPlan FL/IR 60/0.90
W) or 40 (LUMPlan FLN40/0.80W) objectives attached to BX51WI
(Olympus) or SliceScope (Scientifica) microscope equipped with Dodt
gradient contrast optics (DGC; Luigs and Neumann; Dodt and Ziegl-
gansberger, 1998) and collimated light emitting device (LED; 780 nm,
ThorLabs) as transmitted light sources. For prostaglandins and throm-
boxane analysis, parasagittal slices (400 m thick) were microdissected
to isolate the sensorimotor cortex and the underlying white matter.
Vascular reactivity.Diving arterioles in layers I–III were selected under
IR-DGC videomicroscopy on the basis of their well defined luminal di-
ameter (10–30m), their length remaining in the focal plane for at least
50 m (Cauli et al., 2004; Rancillac et al., 2006) and of the thickness of
their wall (4.6  0.2 m, n  89 arterioles; Table 1) indicative of the
presence of smooth muscle cells (Girouard et al., 2010). A resting period
of at least 30 min (Lovick et al., 1999; Zonta et al., 2003) was observed
after slice transfer. To limit the temperature-dependent toxicity of
NMDA in slices (Andrew et al., 1996) images were acquired at room
temperature every 10 s using a digital CCD camera (CoolSnap HQ2,
Roper Scientific, or QIClick, QImaging) and ImagingWorkbench 6.0.25
(INDEC BioSystems) or Image Pro Plus 6.3.1 (MediaCybernetics) soft-
ware. The focal planewasmaintained constantly on-line using parenchy-
mal cells as anatomical landmarks. To compensate for potential x–y
drifts all images were realigned off-line using the “StackReg” plug-in
(The´venaz et al., 1998) of ImageJ 1.48 software. Luminal diameter was
measured on registered images using custom analysis software developed
in MATLAB (MathWorks). To ovoid potential drawbacks due to blood
vessels instability, only arterioles exhibiting a stable luminal diameter
were further taken into account. Arterioles were considered stable if the
relative SD (RSD) of their luminal diameter during an initial baseline
period of 5 min was 5%. Because arterioles have a limited myogenic
tone in brain slices (Fergus and Lee, 1997; Lovick et al., 1999; Cauli et al.,
2004; Rancillac et al., 2006; Mishra et al., 2014), blood vessels were pre-
constricted by superfusing the thromboxane A2 agonist, 9,11-dideoxy-
11a,9a-epoxymethanoprostaglandin F2 (U46619; 50–75 nM). As the
degree of vasoconstriction has been reported to influence the amplitude
and polarity of vascular responses (Blanco et al., 2008), only arterioles
developing a similar and stable vasoconstriction (40.6 1.5%of initial
diameter, RSD10%, n 89 arterioles; Table 1; Movie 1) within the 40
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min following U46619 application were included in the analysis. NMDA
(30 M) was bath-applied for 5 min after 60 min of U46619 superfusion
(Movie 1). COX-1/2 inhibitors and prostaglandin receptor antagonists
were applied 30 min before NMDA application and throughout all the
duration of the experiment. Tetrodotoxin (TTX) was applied 15 min
before NMDA application. Only one arteriole was monitored per slice.
Dilatory responses are expressed as changes relatively to the precon-
stricted state. The magnitude (Bakalova et al., 2002) of vasodilations was
defined as the integral of diameter changes measured for a period of
1000 s following the onset of vasodilation.
Analysis of prostaglandins and thromboxane: collection of supernatants
and slices. Four acute slices and a control slice were placed in two wells of
a 12-well plate filled with 1 ml of oxygenated aCSF containing 50 nM
U46619 and amixture ofO2/CO2 (95%/5%)was continuously delivered.
After an equilibration period of 30 min, 100 l of supernatant were
collected and rapidly frozen in dry ice (t  30 min). One-hundred
microliters of SC 560, NS 398 or their vehicle (DMSO 0.02%) were then
added to the medium. After 30 min of incubation 100 l of supernatant
were collected, rapidly frozen in dry ice (t  0 min), and replaced by a
solution supplemented with NMDA or its vehicle (water). After 2 and 5
min of incubation 100 and900 l were, respectively, collected, frozen,
and replaced by 1ml of aCSF containing COX-inhibitor or its vehicle but
lacking NMDA. One-hundred microliters of supernatant were collected
5 min and 15 min after NMDA washout (t  10 and 20 min, respec-
tively). After 25min, all of the remaining supernatant (i.e.,800l) was
collected and frozen as well as the four slices. Viability of slices after
treatment was evaluated by ensuring that the control slice displayed
numerous healthy-looking cells when observed under IR-DGC
illumination.
Analysis of prostaglandins and thromboxane: equipment. Lipid analysis
was performed using LC-ESI-MS/MS. The LC-MS/MS system consisted
of a hybrid triple quadrupole-ion trap QTrap 5500 mass spectrometer
(AB Sciex) equipped with a Turbo-V-source operating in negative ESI
mode, an Agilent 1200 binary HPLC pump, column oven (40°C) and
degasser (Agilent) and an HTC Pal autosampler (Chromtech) with a
cooling stackwhich kept the samples at 4°C.High-purity nitrogen for the
mass spectrometer was produced by a NGM 22-LC/MS nitrogen gener-
ator (Cmc Instruments).
Analysis of prostaglandins and thromboxane: extraction and mass spec-
trometry. Analysis of prostaglandin content was performed as previously
described (Schmitz et al., 2014). The homogenized tissue pieces and the
slice supernatants were extracted by two rounds of liquid-liquid extrac-
tion with ethylacetate (600 l). The samples were spiked before extrac-
tionwith the internal standardmixture, 100l of 0.15 M EDTA and 10l
BHT (2 mg/ml in methanol) to prevent oxidation of analytes. After vor-
texing and centrifugation for 3 min at 17,000 g, the organic fractions
were combined and evaporated at a temperature of 45°C under a gentle
stream of nitrogen.
LC-MS/MS conditions. For the chromatographic separation a Synergi
Hydro-RP column and precolumn were used (150  2 mm I.D., 4 m
particle size and 80 Å pore size from Phenomenex). A linear gradient was
used at a flow rate of 300l/min. Themobile phase Awaswater/formic acid
(100:0.0025, v/v, pH 4.0) and mobile phase B acetonitrile/formic acid (100:
0.0025, v/v). The sample solvent was acetonitrile/water/formic acid (20:80:
0.0025, v/v, pH 4.0). The total run timewas 16min and injection volume 45
l. Retention times of 6-keto-PgF1, TXB2, PgF2, PgE2, and PgD2were 7.4,
8.0, 8.2, 8.7, and 9.2 min, respectively.
Themass spectrometer was operated in the negative ionmode with an
electrospray voltage of4500 V at 450°C. Multiple reaction monitoring
was used for quantification. The mass transitions used are m/z 351.1
¡m/z 315.0 for PgE2 and PgD2, m/z 353.1¡m/z 309.2 for PgF2, m/z
369.1¡m/z 163.0 for 6-keto-PgF1, m/z 369.1¡m/z 169.1 for TXB2,
m/z 355.1 ¡m/z 275.1 for [2H4]-PgE2 and [2H4]-PgD2, m/z 357.1
¡m/z 313.2 for [2H4]-PgF2, m/z 373.2¡m/z 167.1 for [2H4]-6-keto-
PgF1 andm/z 373.1¡m/z 173.1 for [2H4]-TXB2 all with a dwell time of
50 ms. All quadrupoles were working at unit resolution.
Table 1. Morphological and physiological properties of diving arterioles
Ctrl
(n 16)
Indo
(n 6)
SC 560
(n 12)
NS 398
(n 10)
AH 6809
(n 14)
L 161-982
(n 11)
CAY 10441
(n 12)
TTX
(n 8)
Resting luminal diameter,m 17.3 1.9 14.0 2.5 19.3 2.2 16.1 1.2 14.9 1.4 16.9 2.4 16.6 1.5 16.3 2.2
U(16,6) 36 U(16,12) 78 U(16,10) 80 U(16,14) 95 U(16,11) 79 U(16,12) 93 U(16,8) 61
p 0.407007 p 0.42275 p 1 p 0.49841 p 0.680026 p 0.909139 p 0.880976
n.s.
Wall thickness,m 4.9 0.4 4.6 0.5 4.2 0.4 4.7 0.4 4.9 0.4 5.2 0.5 4.2 0.4 3.9 0.6
U(16,6) 40 U(16,12) 79 U(16,10) 75.5 U(16,14) 110 U(16,11) 76 U(16,12) 83 U(16,8) 37
p 0.590031 p 0.449918 p 0.815935 p 0.951039 p 0.576537 p 0.567585 p 0.105638
n.s.
Resting stability, % 1.2 0.2 1.6 0.2 1.4 0.2 1.5 0.2 1.4 0.2 1.7 0.3 1.4 0.1 1.3 0.2
U(16,6) 25 U(16,12) 73 U(16,10) 57.5 U(16,14) 93 U(16,11) 61 U(16,12) 72 U(16,8) 49
p 0.098026 p 0.301529 p 0.240562 p 0.447547 p 0.194506 p 0.28029 p 0.382604
n.s.
Constriction level, % 46.5 3.2 46.0 6.5 45.1 4.9 39.4 5.0 37.5 3.5 37.2 4.5 37.2 3.5 35.3 4.8
U(16,6) 45 U(16,12) 93.5 U(16,10) 52 U(16,14) 69 U(16,11) 58.5 U(16,12) 57 U(16,8) 37.5
p 0.857733 p 0.909139 p 0.149647 p 0.077067 p 0.14767 p 0.07354 p 0.105638
n.s.
Constriction stability, % 3.4 0.6 3.9 0.7 3.2 0.6 3.1 0.4 3.1 0.5 3.1 0.6 2.6 0.4 2.4 0.2
U(16,6) 35 U(16,12) 92.5 U(16,10) 74 U(16,14) 105 U(16,11) 85 U(16,12) 82 U(16,8) 50
p 0.366773 p 0.873052 p 0.775995 p 0.790107 p 0.903538 p 0.536889 p 0.41665
n.s.
Ctrl, Control; Indo, indomethacin; SC560, COX-1 inhibitor; NS398, COX-2 inhibitor; AH6809, EP1/2 receptor antagonist; L 161-982, EP4 receptor antagonist; CAY10441, IP receptor antagonist; TTX, tetrodotoxin;n, number of divingarterioles.
Values are mean SEMMann–Whitney U test and corresponding exact p values. n.s., not statistically significant from control condition with Bonferroni correction for multiple comparisons.
Movie 1. NMDA induced vasodilation. Diving cortical arteriole visualized in a slice by IR-DGC
was preconstricted with U46619 (50 nM, 310–6000 s). Bath application of 30 M NMDA
(3910–4200 s) reversibly dilated blood vessel. For more details, see Figure 1.
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Quantification. Concentrations of the calibration standards, quality
controls, and unknowns were evaluated by Analyst software (v1.5; B
Sciex). Ratios of peak areas of the lipid and the respective internal stan-
dard (y-axis) were plotted against concentration (x-axis) and calibration
curves for each lipid were calculated by least-square regression analysis
with 1/concentration2 weighting. Variations in accuracy and intraday
and interday precision (n 6 for each concentration, respectively) were
15% over the respective ranges of calibration (0.02–250 ng/ml for
PgE2, PgD2 and 6keto-PgF1; 0.075–250 for TXB2 and 0.08–1000 for
PgF2).
Astrocytes vital staining. Slices were vitally stained by a 20 min super-
fusion of aCSF containing 1 M sulforhodamine 101 (SR101, Sigma-
Aldrich) or 2MTexasRed hydrazide (TxRed; Invitrogen) and rinsed for
at least 10min (Lecrux et al., 2011). SR101 andTxRedwere excited at 535
nm with a LED (CoolLED, Precise Excite) and red fluorescence was
collected using a Triple-beamsplitter 395/495/610 (FF395/495/610-
Di01-25x36, Semrock) and a Tripleband emission filter 425/527/685
(FF01-425/527/685-25, Semrock). IR-DGC and fluorescent Images were
captured with a digital CCD camera (CoolSnap HQ2) and Imaging
Workbench 6.0.25 software.
Whole-cell recordings. Patch pipettes (5.5  0.1 M) pulled from
borosilicate glass were filled with 8 l of RNase free internal solution
containing the following in (mM): 144 K-gluconate, 3 MgCl2, 0.5 EGTA,
10 HEPES, pH 7.2 (285/295 mOsm). Whole-cell recordings were per-
formed at 27.0 0.5°C using a patch-clamp amplifier (Axopatch 200B,
MDS). Data were filtered at 5–10 kHz and digitized at 50 kHz using an
acquisition board (Digidata 1440,MDS) attached to a personal computer
running pCLAMP 10.2 software package (MDS).
Electrophysiological properties were determined in voltage-clamp
mode for astrocytes (Houades et al., 2008; Lecrux et al., 2011) and
current-clamp mode for neurons (Karagiannis et al., 2009). Membrane
potential values were not corrected for liquid junction potential. Input
resistance of astrocytes was determined by plotting a voltage/current
curve of the current response at steady state. This resistance was cor-
rected for series resistance determined by plotting a voltage/current
curve of the capacitive transients (Houades et al., 2008). Resting mem-
brane potential of astrocytes was determined by calculating the intercept
of the voltage/current curve with the 0 pA value. Resting membrane
potential of neurons was measured just after passing in whole-cell con-
figuration. Only neurons with a resting membrane potential more
negative than51 mV were analyzed further. Thirty-two electrophysio-
logical properties chosen to describe the electrophysiological diversity of
cortical neurons (Ascoli et al., 2008) were determined as previously de-
scribed (Karagiannis et al., 2009) using custom analysis software devel-
oped in MATLAB (MathWorks).
Morphological analysis of IR-DGC images. Arteriole wall thickness was
measuredmanually using Image-ProAnalyzer 7.0.0.951 software (Media
Cybernetics). Somatic features were measured from IR-DGC images of
the recorded cells as previously described (Karagiannis et al., 2009).
Briefly, the soma was manually delineated using Image-Pro Analyzer
7.0.0.951 software. Then, the length of major andminor axes, the perim-
eter, and the area were extracted. The soma elongation was calculated as
the ratio between major and minor axes. Roundness was calculated ac-
cording to:
perimeter2
4  area
A value close to 1 is indicative of round somata. Somata with no obvious
process and displaying a roundness value lower than 1.5 was considered
as round. Cells with a soma exhibiting two processes in opposite direc-
tion were defined as fusiform if their elongation was 	2 (Cauli et al.,
2000). If it was2, cells were considered as ovoid. Cells whose soma had
	2 processes were defined as irregular.
Cytoplasm harvest and scRT-PCR. At the end of the whole-cell record-
ing lasting20min, the cytoplasmic content was aspirated in the record-
ing pipette. The pipette’s contentwas expelled into a test tube andRTwas
performed in a final volume of 10 l, as described previously (Lambolez
et al., 1992). Two scRT-PCR protocols were designed to probe simulta-
neously for the expression of prostaglandin synthesizing enzymes and
well established markers of cortical astrocytes (Houades et al., 2008) or
neurons (Ascoli et al., 2008; Karagiannis et al., 2009). Prostaglandin-
synthesizing enzymes included COX-1 and COX-2, the terminal PgE2
synthases (PGES); mPGES1, mPGES2, and cPGES, and PgI2 synthase
(PGIS). Astrocytes markers included S100 and glial fibrillary acidic
protein (GFAP). Neuronal markers included the vesicular glutamate
transporter, vGluT1, the two isoforms of glutamic acid decarboxylase
(GAD65 and GAD67), the neuronal isoform of nitric oxide synthase
(NOS-1), calbindin (CB), calretinin (CR), parvalbumin (PV), neuropep-
tide Y (NPY) or vasoactive intestinal polypeptide (VIP), somatostatin
(SOM), and cholecystokinin (CCK). Two-steps amplification was per-
formed essentially as described previously (Cauli et al., 1997) using the
primer pairs listed in Table 2. Ten microliters of each individual PCR
product were run on a 2% agarose gel stained with ethidium bromide
using
X174 digested by HaeIII as a molecular weight marker.
Double-fluorescence labeling. Rats were deeply anesthetized with so-
dium pentobarbital (50mg/kg, i.p.) and their brain were perfusion-fixed
(500 ml of ice-cold 4% paraformaldehyde (PFA), in 0.1 M phosphate
buffer, pH 7.4), and postfixed by immersion in 4%PFA (2 h, 4°C). Brains
were then cut in 50-m-thick coronal sections with a HM 650V vi-
bratome (Microm). Sections from three to four different rat brains were
simultaneously incubated overnight with the primary antibodies against
COX-2 and specific markers. Antibodies included goat anti-COX-2 (1:
2000; sc-1747, Santa Cruz Biotechnology; Damm et al., 2011), rabbit
anti-ionized calcium-binding adapter molecule 1 (Iba-1, 1:1000, no.
019-19741, Wako Pure Chemical Industries; Lloyd-Burton and
Roskams, 2012), rabbit anti-S100 (1:2000, no. 37, Swant; Horky et al.,
2006), rabbit anti-Satb2 (1:1000, ab34735, Abcam; S. Lee et al., 2010).
The respective immunoreactions were visualized with the following sec-
ondary antibodies: donkey-anti goat AlexaFluor 555 (1:400, A21432, In-
vitrogen), donkey-anti mouse AlexaFluor 488 (1:400, A21202,
Invitrogen), and donkey-anti rabbit AlexaFluor 488 (1:400, A21206, In-
vitrogen). The vascular bed was labeled with biotinylated lycopersicon
esculentum agglutinin (LEA; 10 g/ml, B-1175, Vector Laboratories;
Mazzetti et al., 2004) and revealed with AlexaFluor 488 streptavidin (1:
400, S-11223, Invitrogen). Sections were mounted with Vectashield
(Vector Laboratories) on gelatin-coated slides for visualization. Images
of immunostained material were acquired using a TCS SP5 confocal
microscope with a 20 objective (20HC Plan APO IMMCORCS NA
0.7/Oil) and LAS AF software (Leica Microsystems). Cell counting and
image processing were performed using Image Pro Plus 4.1.0.0 and Im-
age Pro Analyzer 7.0.0.951 (MediaCybernetics) respectively.
NVC to whisker stimulation using laser Doppler flowmetry (LDF). Rats
were anesthetized (urethane, 1 g/ml, i.p.), cannulated in the femoral
artery for blood gas and blood pressure measurements, and placed in a
stereotaxic frame (David Kopf Instruments). Body temperature was
maintained at 37°C using a rectal probe connected to a homeothermic
blanket (Harvard apparatus). The posterior atlanto-occipital membrane
was exposed for intracisternal injection (3 l, 1 l/min) of vehicle and
drugs using a 30 G needle connected to a 10 l Hamilton syringe driven
by a Harvard infusion pump, as previously described (Lecrux et al.,
2011). All drugs effects were measured on whisker stimulation at 20 min
after intracisternal injection. CAY 10441 and its vehicle slightly, but sig-
nificantly, affected baseline blood flow. Left whiskers were trimmed, at-
tached to a glass capillary connected to a Piezo actuator (Piezo Systems)
placed in a Faraday cage and driven by an isolated pulse stimulator (8Hz,
A-M Systems, Model 2100) controlled by PowerLab (AD Instruments).
Seven stimulation blocks (40 s baseline, 20 s stimulation) were given for
each condition (control, vehicle, and drug) with only one drug being
tested in each rat. The skull over the right barrel cortex was thinned to
translucency for positioning of the laser-Doppler probe (wavelength: 785
nm, 0.58 mm diameter, 0.5 mm transmit/receive spacing, Transonic
Systems). Following placement of the laser Doppler probe over the most
responsive region of the barrel cortex, a tungsten microelectrode (FHC)
was inserted using stereotaxic manipulators with an angle (40°) in the
cortical depth (1 mm) as close as possible (1.5 mm) of the LDF probe
for simultaneous local field potential (LFP) recordings and another mi-
croelectrode was positioned symmetrically in the corresponding ipsilat-
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Table 2. PCR primers
Genes accession no. First PCR primers Size, bp Second PCR nested primers Size, bp
GFAP Sense, 454: AAGCTCCAAGATGAAACCAACCT 631 Sense, 509 ACAGACAGGAGGCGGATGAA 263
NM_017009 (Lambolez et al., 1992) (Lecrux et al., 2011)
Antisense, 1066: CGATCTCGATGTCCAGGGC Antisense, 749 GGACCGATACCACTCTTCTGTTT
(Lambolez et al., 1992) (Lecrux et al., 2011)
S100 Sense, 45: CCATCAGTATTCAGGGAGAGAGGG 166 Sense, 58: GGGAGAGAGGGTGACAAGCA 132
NM_013191.1 (Lecrux et al., 2011) (Lecrux et al., 2011)
Antisense, 191: GTCACACTCCCCATCCCCAT Antisense, 170: TTCGTCCAGCGTCTCCATCA
(Lecrux et al., 2011) (Lecrux et al., 2011)
vGluT1 Sense, 361: GGCTCCTTTTTCTGGGGGTAC 259 Sense, 373: TGGGGGTACATTGTCACTCAGA 201
NM_053859.1 (Gallopin et al., 2006) (Gallopin et al., 2006)
Antisense, 600: CCAGCCGACTCCGTTCTAAG Antisense, 553:ATGGCAAGCAGGGTATGTGAC
(Gallopin et al., 2006) (Gallopin et al., 2006)
GAD65 Sense, 713: TCTTTTCTCCTGGTGGTGCC 391 Sense, 743: TGTACGCCATGCTCATTGCC 312
NM_012563.1 (Bochet et al., 1994) (Gallopin et al., 2006)
Antisense, 1085: CCCCAAGCAGCATCCACAT Antisense, 1032: CAGCTACAGCCAAGAGAGGATCA
(Bochet et al., 1994) (Gallopin et al., 2006)
GAD67 Sense, 529: TACGGGGTTCGCACAGGTC 599 Sense, 581: TGGATATCATTGGTTTAGCTGGC 508
NM_017007.1 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 1109: CCCCAAGCAGCATCCACAT Antisense, 1065: TCACATATGTCTGCAATCTCCTGG
(Cauli et al., 1997) (Gallopin et al., 2006)
NOS-1 Sense, 2816: AACTGGGAGGGGAGAGGATTC 548 Sense, 2829: GAGGATTCTGAAGATGAGGGAGG 517
NM_052799.1 (Cauli et al., 2004) Antisense, 3323: CCTTCCAATTACTGATGACACCC
Antisense, 3323: GGGTGGGAGGCGAGATTCAT
(Cauli et al., 2004)
CB Sense, 134: AGGCACGAAAGAAGGCTGGAT 432 Sense, 166: CCTGAGATGAAAACCTTTGTGG 249
NM_031984.2 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 544: TCCCACACATTTTGATTCCCTG Antisense, 392: CACGGTCTTGTTTGCTTTCTCTA
(Cauli et al., 1997) (Gallopin et al., 2006)
PV Sense, 115: AAGAGTGCGGATGATGTGAAGA 388 Sense, 151: CTGGACAAAGACAAAAGTGGCT 244
NM_022499.2 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 480: TTGTTTCTCCAGCATTTTCCAG Antisense,376: AGAAGGGCTGAGATGGGGC
(Cauli et al., 1997) (Gallopin et al., 2006)
CR Sense, 142: CTGGAGAAGGCAAGGAAAGGT 309 Sense, 157: AAAGGTTCTGGCATGATGTCC 265
NM_053988.1 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 429: AGGTTCATCATAGGGACGGTTG Antisense, 401: TCAGGAGGTCGGACAGAAATC
(Cauli et al., 1997) (Gallopin et al., 2006)
NPY Sense,45: GCCCAGAGCAGAGCACCC 359 Sense,21: CAGAGACCACAGCCCGCC 302
NM_012614.1 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 292: CAAGTTTCATTTCCCATCACCA Antisense, 261: CTTCAAGCCTTGTTCTGGGG
(Cauli et al., 1997) (Gallopin et al., 2006)
VIP Sense, 189: TGCCTTAGCGGAGAATGACA 287 Sense, 208: ACGCCCTATTATGATGTGTCCAG 214
NM_053991.1 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 456: CCTCACTGCTCCTCTTCCCA Antisense, 402: TTTGCTTTCTAAGGCGGGTG
(Cauli et al., 1997) (Gallopin et al., 2006)
SOM Sense, 43: ATCGTCCTGGCTTTGGGC 208 Sense, 75: GCCCTCGGACCCCAGACT 150
NM_012659.1 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 231: GCCTCATCTCGTCCTGCTCA Antisense, 207: TGGGGCAAATCCTCAGGC
(Cauli et al., 1997) (Gallopin et al., 2006)
CCK Sense, 177: CGCACTGCTAGCCCGATACA 216 Sense, 192: ATACATCCAGCAGGTCCGCA 151
NM_012829.1 (Cauli et al., 1997) (Gallopin et al., 2006)
Antisense, 373: TTTCTCATTCCGCCTCCTCC Antisense, 320: TGGGTATTCGTAGTCCTCAGCAC
(Cauli et al., 1997) (Gallopin et al., 2006)
COX-1 Sense, 27: GTTTCCCCTGCTGCTGCTC 359 Sense, 137: AGGGTGTCTGTGTCCGCTTC 185
NM_017043.1 (Lecrux et al., 2011) (Lecrux et al., 2011)
Antisense, 366: GGCTGGGGATAAGGTTGGAC Antisense, 301: GGCATTCACAAACTCCCAGAT
(Lecrux et al., 2011) (Lecrux et al., 2011)
COX-2 Sense, 199: CTGAAGCCCACCCCAAACAC 247 Sense, 202: AAGCCCACCCCAAACACAGT 206
NM_017232.2 (Lecrux et al., 2011) (Lecrux et al., 2011)
Antisense, 426: TGGGAGTTGGGCAGTCATCA Antisense, 384: CTGGTGTAGTAGGAGAGGTTGGAG
(Lecrux et al., 2011) (Lecrux et al., 2011)
mPGES1 Sense, 9: CCTGGGTTTGGTGATGGAGAA 362 Sense, 36: GGTGCTCCCCGCCTTTCT 290
NM_021583.2 Antisense, 350: GGTTCATTTTGCCCAGGTAGG Antisense, 303: TGAGGACCACGAGGAAATGTATC
mPGES2 Sense, 358: GACTTCCACTCCCTGCCCT 348 Sense, 381: GGTGGTAGAGGTGAATCCCG 291
NM_001107832.1 Antisense, 686: CTGCCGCCACTTCATCTCCT Antisense, 652: TTTCCGCCATACATCTGCTG
cPGES Sense,18: GCCCTCTGCCCCGTTCAC 305 Sense, 26: ACGACCGAAGGGACTATGTATT 187
NM_001130989.1 Antisense, 266: GCTTTGCCCTTTCCTTTGTTA Antisense, 191: CTGTCCGTTCTTTTATGCTTGG
PGIS Sense, 1142: GTGACCGCCTTCTCCTCTTTC 240 Sense, 1174: CCCCAGAAGGACCCAGAAATC 190
NM_031557.2 Antisense, 1361: TCAGCAGCAGGACCACAAACT Antisense, 1342: ACTGTTTGATGCTGTTGATGGC
Note: Position 1, first base of the start codon.
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eral barrel cortex. Recordings of LFPs were
performed through a 2-channel amplifier
(A-M Systems, model 1800), a reference screw
being placed on the dura over the frontal cor-
tex. Electrophysiological data were filtered
(10–500Hz), amplified and acquired at 10 kHz
through a PowerLab (AD Instruments) and
analyzed using script written in MATLAB
(MathWorks). LDF data were extracted for ev-
ery second using LabChart software (AD in-
struments), and whisker-evoked cerebral
blood flow (CBF) changes over baseline for the
seven stimulation blocks were averaged. LFPs
on the contralateral and corresponding ipsilat-
eral barrel cortex were averaged every 125 ms
for each 20 s stimulation, and the LFP ampli-
tude, defined as the difference between the
maximal and minimal values, was averaged
over the repeated blocks and normalized from
control condition.
Laser-speckle contrast imaging and optoge-
netic stimulation. Mice were anesthetized with
5% isoflurane in air, and then reduced to
1–1.5% during surgery. Body temperature was
maintained at 37  0.5°C by a heating pad
which had its intensity controlled by tempera-
ture feedback from a rectal probe. The mouse
was secured in a custom-made head hold using
cyanoacrylate and dental cement and a crani-
otomywasmade over the right forelimb senso-
rimotor cortex. The dura was left intact.
Agarose dissolved in HEPES buffered aCSF,
pH 7.3, to 1.5% was placed over the surface of
the cortex at 37°C. The surface of the cortex
was then coveredwith a no.1 130, 160mthick
glass coverslip. Before imaging, the brain was
warmed to 37°C by pumping warm water
through tubing attached to the custom built
stainless steel head hold (Xie et al., 2013). Dur-
ing stimulation procedures anesthesia was
switched to a ketamine/xylazine combination
(100/10 mg/kg) that was supplemented as
required.
The surface of the cortex was illuminated
with a 784 nm 32 mW StockerYale SNF-
XXX_885 s-35 laser (Stocker and Yale) with a
beam expander directed at the cortex at a 30°
angle. Light intensity was controlled with a po-
larizer. The flow of blood cells and resultant
blurring in the interference patterns (Briers,
2001) was detected by a CCD camera (Dalsa 1M60). Image acquisition
was performed using EPIX XCAP software (v2.2). Ten trials for each
stimulation parameter consisting of 100–130 frames were acquired at 10
Hz with a 10 ms exposure time. Using MATLAB (MathWorks) each
1024 1024 pixel image in the stack was variance filtered spatially with a
kernel size of 3 pixels. Blood flow measurements were estimated as the
inverse square of speckle contrast values whichwere scaled betweenmin-
imum and maximum flow rate (Cheng and Duong, 2007). Minimum
flow was determined from contrast values measured from the mouse
cortex after the animal was killed. For stimulation a 473 nm laser beam
(Crystalaser, collimated to100mdiameter, 5ms pulses, 3.3mW, 100
Hz, 1 s) was targeted to forelimb sensorimotor cortex (Scott and Mur-
phy, 2012). Light from the 473 nm laser was blocked from contaminating
the speckle signal as detected by the camera by a 715 nm long-pass filter.
Regions of interest selected for assessment of speckle contrast over time
were 1mm2 and centered at the site where the laser was targeted over the
cortex.
After baseline assessment of light-evoked hemodynamic responses the
agarose was removed from the cortical surface and NS 398 was adminis-
trated directly on the cortex for 30min. Agarosewas then reapplied to the
cortex (37°C), covered with a coverslip, and laser speckle contrast imag-
ing ensued. The magnitude of CBF change was defined as the integral of
CBF changes measured from the onset of stimulation to the end of the
recording.
Drugs.U46619,NMDA, SC 560,NS 398, AH6809; and L 161-982were
purchased from Enzo Life Sciences, CAY 10441 from Cayman chemical,
Indomethacin from Sigma-Aldrich and TTX from Latoxan.
Statistical analyses. Statistical analyses were performed with Prism4
(GraphPad Software) or Statistica 6 (Statsoft). All values are expressed as
mean  SEM. Normality of distributions and equality of variances were
assessed using the Shapiro–Wilk test and the F test, respectively. Parametric
tests were only used if these criteria were met. Bonferroni correction was
used formultiple comparisons. Statistical significance on all figures uses the
following convention: *p 0.05, **p 0.01, ***p 0.001.
Statistical significance of vascular responses, morphological and elec-
trophysiological properties, and light-induced CBF responses between
Thy1-YFP and Emx1-Cre;Ai32 mice was determined using the Mann–
Withney U test. Comparison of the occurrence of expressed genes be-
tween different cell types was determined using Fisher’s exact test.
Figure 1. Characterization of NMDA-induced vasodilations. A, Diameter changes induced by 5 min bath applications of NMDA
(30M; black bar and vertical gray zone). The SEM envelopes the mean traces. The horizontal dashed lines represent the initial
diameters. The vertical scale bar indicates the relative diameter changes. Under control conditions (Ctrl, black, n 16 arterioles
from12 rats)NMDA induces vasodilations.NonselectiveCOX-1/2 inhibitionby indomethacin (Indo;magenta,n6arterioles from
3 rats) dramatically reduced the vascular responses. COX-1 inhibition by SC 560 (purple, n 12 arterioles from9 rats) did not alter
the vascular response in contrast to the selective inhibition of COX-2 by NS 398 (red, n 10 arterioles from 8 rats). Antagonism of
EP2, EP4, and IP receptors respectively by AH 6809 (orange, n 14 arterioles from 13 rats), L 161–982 (green, n 11 arterioles
from 6 rats) and CAY 10441 (blue, n 12 arterioles from 7 rats) reduced the vascular responses. Blockade of action potentials by
TTX (brown, n  8 arterioles from 3 rats) dramatically reduced the vascular responses. B, Representative example showing
infrared images of a preconstricteddiving arteriole that reversibly dilated toNMDAapplication. Pial surface is upward. Scale bar, 20
m.White dashed vertical lines indicate the initial position of the vessel wall. C, D, Effects of COX-1/2 inhibition, EP2, EP4, and IP
receptor antagonism, and action potentials blockade on maximal amplitude (C) and magnitude (D) of NMDA-induced vasodila-
tions. Dots represent individual arteriolar responses. Bars and error bars correspond to themean SEM. *, **, and *** statistically
different from Ctrl condition with p 0.05, 0.01 and 0.001, respectively; n.s., not statistically significant.
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Statistical significance of light-induced CBF responses before and after
NS 398 application was determined using a paired t test. Drug effects on
CBF (at the maximum dose and time efficacy determined in preliminary
experiments), LFP, blood gases, blood pressuremeasurements, and pros-
taglandin analysis were compared by repeated-measures ANOVA, fol-
lowed by a post hoc Newman–Keuls test between each condition. When
normality of distribution was not met, the Friedman test was used.
Results
COX-2-derived prostaglandins mediate
NMDA-induced vasodilations
To identify the prostaglandins involved in NVC, we focused on
NMDA receptors for the following reasons: (1) their activation
promotes in vivo the release of the vasodi-
latory PgE2 and PgI2 (Lazarewicz and
Salin´ska, 1995; Pepicelli et al., 2005). (2)
Similar to COX-2, their activity accounts
for approximately one-half of the NVC
responses to various sensory stimuli
(Niwa et al., 2000; Norup and Lauritzen,
2001; Bakalova et al., 2002; Gsell et al.,
2006; Stefanovic et al., 2006; Lecrux et al.,
2011). (3) NMDA receptors blockade oc-
cludes the reduction of the NVC re-
sponses induced by COX-2 inhibition
(Lecrux et al., 2011), suggesting that most
of the NVC response evoked by NMDA
receptors is due to the release and action
of vasodilatory prostaglandins. Finally,
(4) NMDA has been shown to dilate cor-
tical arterioles in acute cortical slices (Fer-
gus and Lee, 1997; Lovick et al., 1999).
Because thebrain slicepreparationoffers
a well controlled extracellular environment
suitable for pharmacologicalmanipulations
(Iadecola and Nedergaard, 2007) and pros-
taglandin measurement (Gordon et al.,
2008), we first sought to determinewhether
vasodilatory prostaglandins could mediate
theNMDA-induced vasodilations in young
rats.We chose this approach as a good com-
promise for preservation of slice quality,
easily achieved in young animals and essen-
tial to preserve neurovascular physiology,
and a phenotype of the neuro-glio-vascular
unit close toadulthood(Mishraet al., 2014).
Indeed, COX-2 expression (Yamagata et al.,
1993;Kaufmann et al., 1996; Tocco et al.,
1997), astrocyte phenotype (Stichel
et al., 1991; Zhou et al., 2006; Houades et al., 2008) and vas-
cular patterns (Harb et al., 2013; Whiteus et al., 2013; Lacoste
et al., 2014) maturate during the end of the third postnatal
week.
We used 30 M NMDA, a submaximal concentration eliciting
large vasodilations (Fergus and Lee, 1997) compatible with their phar-
macological investigations (Mishra et al., 2014). Bath application of
NMDA, dilated preconstricted cortical arterioles (maximal dilation
84.711.9%,magnitude47.77.6103%  s;Fig. 1;Table1;Movie1).
Inamajorityofarterioles(n10of16),NMDAdidnotfullybringback
luminal diameters to their preconstriction value (83.2 3.5%). How-
Figure 2. Vasodilatory prostaglandins release dynamics induced byNMDA. Dynamics of PgE2 (A) and 6-keto PgF1 (B) levels in
the supernatants (left) and in the slices after treatments (right). Samples were collected before adding COX inhibitors (t30),
before (t 0min) and during (t 2 and 5min) NMDA (30M; black bar and vertical gray zone), and after removing NMDA (t
10, 20 and 30 min). PgE2 (A) and to a lesser extent and 6-keto PgF1 (B) levels increased during NMDA application (NMDA, black
traces) but not after NMDA removal. No change was observed when applying NMDA vehicle (water, Ctrl, gray traces) or when
NMDAwas applied in presence of NS 398 (red traces) or SC 560 (purple traces). Tissue content (right) in PgE2 (A) and 6-keto PgF1
(B) were elevatedwhen sliceswere treatedwith NMDA in absence of COX inhibitor. Numbers in parenthesis represent the number
of replicates. Error bars are SEM.
Table 3. In vitro IC50 and concentrations of various COX inhibitors and prostaglandin receptor antagonists used for inhibition in tissue
Inhibitor/antagonist In vitro IC50 (or Ki )
Concentrations used for inhibition in brain tissue
Preparation Concentration
Indomethacin COX-1: 22 nM COX-2: 87 nM Brain slices 5M
(Lora et al., 1998) (Zonta et al., 2003)
SC 560 COX-1: 9 nM COX-2: 6.3M Brain slices 100 nM
(Smith et al., 1998) (Blanco et al., 2008)
NS 398 COX-1: 50M COX-2: 0.6M Brain slices 10M
(Lora et al., 1998) (Slanina and Schweitzer, 2005)
AH 6809 EP1: 1.3M (Ki ) EP2: 0.5M (Ki ) Isolated cerebrovascular arterioles 10M
(Boie et al., 1997) (Myren et al., 2010; Dabertrand et al., 2013)
L 161-982 EP4: 100 nM Brain slices 1M
(Machwate et al., 2001) (Hall et al., 2014)
CAY 10441 IP: 7 nM Not available
(Bley et al., 2006)
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ever in some cases (n 6 of 16) it further dilated arterioles by 12.0
3.5%.
To evaluate whether the biosynthesis of vasodilatory prosta-
glandins was involved, slices were pretreated with the nonselec-
tive COXs inhibitor indomethacin at 5 M (Table 3). This
treatment abolished almost completely the NMDA responses
(maximal dilation: 25.0  5.0%, p  0.002412, U(16,6)  9,
Mann–Whitney U test; magnitude: 2.9  5.0 103 %  s, p 
0.000804, U(16,6)  6, Mann–Whitney U test; Fig. 1) indicating
that vasodilatory prostaglandins are recruited during NMDA-
induced vasodilations.Wenext determined the relative contribu-
tion of COX-1 and COX-2 to these responses. Selective COX-1
inhibition with SC 560 (100 nM; Table 3)
did not alter the maximal amplitude
(83.5  14.7%, p  0.766584, U(16,12) 
89, Mann–Whitney U test) or the magni-
tude of the vasodilations (50.2 11.9 103
%  s, p 0.873052,U(16,12) 92, Mann–
Whitney U test; Fig. 1). However, during
the 5 min of NMDA application the
peak of vasodilation was lower in the
presence of SC 560 (17.0  4.9%) than
in control condition (38.2  8.4%, p 
0.000204, U(16,12) 16, Mann–Whitney
U test; Fig. 1A), suggesting that COX-1-
derived prostaglandins may participate
in the initial phase of the NVC response.
In contrast with SC 560, and similarly
to indomethacin, selective COX-2 inhibi-
tion with NS 398 (10 M; Table 3) dra-
matically reduced the maximal amplitude
(29.3 5.3%, p 0.000555,U(16,10) 18,
Mann–WhitneyU test; Fig. 1) andmagni-
tude of the response (10.1 3.8 103 %  s,
p 0.000910,U(16,10) 20, Mann–Whit-
neyU test; Fig. 1). NS 398 strongly dimin-
ished the maximal response during the 5
min of NMDA application (14.1 4.1%,
p  0.000025, U(16,10)  0, Mann–Whit-
neyU test; Fig. 1A). Similarly to the in vivo
context (Niwa et al., 2000, 2001; Bakalova
et al., 2002; Stefanovic et al., 2006; Lecrux
et al., 2011) our observations demonstrate
a prominent role of COX-2metabolites in
NVC validating therefore this ex vivo ap-
proach. We also report that the initial
phase of the NVC response to NMDA is
sensitive to SC 560 and NS 398.
To identify the nature of the dilatory
prostaglandins involved, we antagonized
the vasodilatory PgE2 and PgI2 receptors.
Since there is no commercially available
selective EP2 antagonist, we used the EP2/
EP1 antagonist AH 6809 (10 M; Table 3). AH 6809 strongly
reduced the maximal amplitude (35.8  7.2%, p  0.002069,
U(16,14) 40,Mann–WhitneyU test; Fig. 1) and themagnitude of
NMDA-induced vasodilations (16.7  4.9 103%  s, p 
0.003321, U(16,14) 43, Mann–Whitney U test; Fig. 1). We next
thought to block EP4 receptors with its selective antagonist L
161-982 (1 M; Table 3). L 161-982 significantly impaired the
maximal amplitude (43.8 11.9%, p 0.019827, U(16,11) 41,
Mann–Whitney U test; Fig. 1) but not the magnitude of vasodi-
lations (23.0 7.8% 103%  s, p 0.026246,U(16,11) 43, Man-
n–Whitney U test; Fig. 1). Blockade of IP receptor was achieved
with CAY 10441 (200 nM; Table 3). CAY 10441 reduced themax-
imal amplitude (36.3 5.2%, p 0.000670,U(16,12) 26, Man-
n–Whitney U test; Fig. 1) and the magnitude of vasodilations
(18.5 4.6 103%  s, p 0.003711,U(16,12) 35,Mann–Whitney
U test; Fig. 1). The reduction of NMDA-induced vasodilations by
EP2, EP4, and IP receptor antagonists and during COX-2 or
COX-1 inhibition suggests that PgE2 and PgI2 essentially derived
from COX-2 activity underlie these vascular responses.
Figure 3. Effects of EP2, EP4, and IP receptors blockade on the NVC response to sensory stimulation. A, Whisker stimulation
(gray zone, top black bar) induced increases in CBF in the contralateral barrel cortex under control conditions (Ctrl; black lines). The
evoked responsewas not altered by vehicle (gray line),whereas the EP1/EP2 receptor antagonist AH6809 (orange,n6 rats) and
EP4 receptor antagonist L 161–982 (green, n 4 rats), but not the IP receptor antagonist CAY 10441 (blue, n 5 rats), decreased
this response. TheSEMenvelopes themean traces.B,C,Maximalwhisker-evoked changes inCBF (B) and inLFPs (C), underbaseline
(CBF: 8.0 1.1%, 10.9 1.3%, and 8.6 1.2%; LFPs: 100.0 16.7%, 100.0 27.0%, and 100.0 20.8%) and vehicle (CBF:
8.7  1.0%, 11.9  1.2% and 9.0  1.5%; LFPs: 122.3  30.8%, 105.0  14.6%, and 115.4  31.3%) conditions and
application of AH 6809 (CBF: 5.9 1.3%; LFPs: 126.6 30.8, n 6 and 4 rats, respectively), L 161–982 (CBF: 8.7 2.1%; LFPs:
101.9 17.0%, n 4 rats) or CAY 10441 (CBF: 7.9 1.1%; LFPs: 135.0 38.4%, n 5 and 3 rats, respectively). Whisker
stimulation induced increases in theamplitudeof the LFPs in the contralateral barrel cortex as shownby the representative tracings
(average of 7 trials from 1 rat) for each compound (C, top). Contralateral LFP amplitudes were normalized by themean amplitude
under baseline conditions. *p 0.05 and **p 0.01 compared with vehicle conditions,p 0.05 compared with Ctrl condi-
tions, n.s., not statistically significant. Dots represent individual responses. Horizontal bars and error bars representmean SEM.
Table 4. In vivo neurovascular coupling response impairment by receptor
antagonists
Antagonist Concentration
Effect on the peak CBF
whisker response n
AH 6809 107M 5.7 4.5% 4
106M 28.2 2.6% 5
105M 15.0 3.8% 6
104M 6.1 3.8% 5
L 161-982 104M 17.7 4.8% 4
CAY 10441 106M 10.2 11.8% 3
105M 10.4 22.1% 3
104M 0.6 8.7% 5
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NMDA promotes the biosynthesis and
release of PgE2 and PgI2 in
cortical slices
To confirm that PgE2 and PgI2 are indeed
produced and released byNMDAapplica-
tions we sought to measure the content in
PgE2 and 6-keto prostaglandin F1 (6-
keto PgF1), the stable metabolite of PgI2,
produced in slices before, during and after
NMDA application in presence or ab-
sence of COX inhibitors (Fig. 2). Pro-
staglandins and thromboxane were
measured by LC-ESI-MS/MS which per-
mits an unambiguous identification of
prostaglandins (Schmidt et al., 2005,
2014). Because the amount of PgE2 that
can be released by slices is very low (Gor-
don et al., 2008), four slices were coincu-
bated each time. Prostaglandin analysis
was performed in the supernatant at dif-
ferent time points and in the tissue at the
end of the treatments (Fig. 2).
The temporal profile of PgE2 content
(Fig. 2A) was significantly altered when
slices were treated by NMDA (p 
0.00514, Q(7,3)  20.21, Firedman test),
but not when NMDA was omitted (p 
0.09697,Q(7,3) 12.11, Firedman test) or
when NMDA was applied in presence of
NS 398 (p 0.19886,Q(7,3) 9.82, Fired-
man test) or SC 560 (p  0.19417, Q(7,2)
 9,90, Firedman test). Similarly to PgE2,
the temporal profile of 6-keto PgF1 (Fig.
2B) was modified by NMDA treatment
(p 0.03266,Q(7,3) 15.27 with NMDA
and p  0.24846, Q(7,3)  9,06 without
NMDA, Firedman tests) but not in pres-
ence of NS 398 (p  0.34416, Q(7,3) 
7.87, Firedman test) or SC 560 (p 
0.49799, Q(7,2) 6,36, Firedman test).
Figure 4. Expression of COX-2 in the neuro-glio-vascular unit. Representative single plane confocal images of double fluores-
cence staining showing the constitutive expression of COX-2 (red). Scale bar, 100m. *Denotes diving blood vessels. Dashed lines
represent layer I–II border. Pial surface is upward. A, COX-2 immunolabeling is absent from the vascular bed stained with LEA
(green) and (B) from microglia immunostained for Iba-1. C, S100 immunostained astrocytes (green) are essentially COX-2-
negative. D, COX-2-immunopositive cells are Satb2-positive (green).
Table 5. Physiological parameters in rats during whisker stimulation
Compound Condition MAP, mmHg HR, beats/min pH pCO2 , mmHg pO2 , mmHg
AH 6809 Control 79.1 5.6 382.7 14.4 7.44 0.02 41.7 0.6 90.7 3.2
Vehicle 78.9 5.8 374.6 17.5 7.43 0.01 42.7 1.6 91.3 3.0
MAP, HR Drug 79.2 5.3 376.7 20.3 7.44 0.01 41.3 0.9 90.0 3.0
(n 6 rats) Q(2,6) 1.00000 Q(2,6) 0.3333333 Q(2,4) 1.50000 F(2,8) 0.04450 F(2,8) 1.027
pH (n 4 rats) p 0.60653 p 0.84648 p 0.47237 p 0.9074 p 0.3974
pCO2 , pO2 n.s. n.s. n.s. n.s. n.s.
(n 5 rats)
L 161-982 Control 74.7 4.9 398.2 37.3 7.42 0.01 36.0 4.8 101.1 9.7
Vehicle 74.3 6.5 401.9 43.8 7.43 0.01 38.5 1.6 91.4 1.5
MAP, HR, pH, pO2 Drug 73.5 6.8 377.5 30.0 7.42 0.02 36.3 3.8 105.6 7.7
(n 4 rats) F(2,6) 0.1294 F(2,6) 2.689 F(2,6) 0.2572 F(2,4) 0.7467 F(2,6) 1.621
pCO2 p 0.8037 p 0.1930 p 0.7263 p 0.4786 p 0.2923
(n 3 rats) n.s. n.s. n.s. n.s. n.s.
CAY 10441 Control 76.1 5.2 384.3 13.0 7.42 0.01 38.4 2.8 96.6 1.7
Vehicle 78.3 6.6 394.3 16.8 7.42 0.01 40.9 2.0 93.4 3.4
(n 5 rats) Drug 77.5 6.1 371.2 14.8 7.42 0.02 38.8 1.9 89.9 3.6
F(2,8) 1.046 F(2,8) 2.112 Q(2,5) 1.20000 Q(2,5) 2.80000 F(2,8) 4.616
p 0.3676 p 0.2090 p 0.54881 p 0.2466 p 0.0970
n.s. n.s. n.s. n.s. n.s.
Mean arterial blood pressure (MAP), heart rate (HR), pH, and blood gases (pCO2 and pO2 ) were measured during whisker-induced CBF responses under control conditions, as well as after vehicle and drug infusion. None of the compounds
used affected physiological parameters. The number of rats is indicated within parentheses. Repeated-measures ANOVA (F) or Friedman test (Q) and corresponding exact p values. n.s.; not statistically significant.
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PgE2 content in the supernatant reached a maximum of 54
28 pg/ml) 5 min after the application of NMDA (Fig. 2A) and
remained elevated in the tissue after NMDA treatment without
COX inhibitor (32 22 pg/4 slices). Although in the supernatant
the content in 6-keto PgF1 was often below the lower limit of
quantification (see Materials and Methods), during NMDA ap-
plication amaximal level of 6-keto PgF1  (9 8 pg/ml) could be
reached after 5 min and was reliably quantifiable in the tissue
after NMDA treatment without COX inhibitor (23  13 pg/4
slices; Fig. 2B).
Similarly to previous in vivo observations (Lazarewicz and
Salin´ska, 1995; Pepicelli et al., 2005; Anrather et al., 2011), our ex
vivo data confirm that NMDA promotes the release of PgE2 and,
to a lesser extent, of 6-keto PgF1, dependent on COX-1 and
COX-2 activity, hence supporting the recruitment of the
PgE2 and PgI2 vasodilatory receptors in NMDA-induced
vasodilations.
The NVC response to sensory stimulation recruits PgE2
vasodilatory receptors
Our ex vivo data have indicated that NMDA-induced vasodila-
tions are mediated by the release of PgE2 and PgI2 chiefly derived
form COX-2 activity and activation of EP2, EP4, and IP recep-
tors. Because NVC responses to sensory stimulations also involve
NMDA receptors and COX-2metabolites (Niwa et al., 2000; No-
rup and Lauritzen, 2001; Bakalova et al., 2002; Gsell et al., 2006;
Stefanovic et al., 2006; Lecrux et al., 2011)we sought to determine
whether EP2, EP4, and IP receptors were involved in the NVC
response to sensory stimulation and in adult animals.
It has been recently estimated that in vivo the majority of the
CBF increase in response to sensory stimulation is mediated by
capillaries dilation (Hall et al., 2014). We used LDF to obtain a
global readout of CBF changes including layer IV of the somato-
sensory cortex which exhibits the highest neuronal and capillary
density (Woolsey et al., 1996; Tsai et al., 2009) and where the
NVC response initiates and propagates to upstream diving arte-
rioles (Silva andKoretsky, 2002; Tian et al., 2010;Hall et al., 2014;
Filosa et al., 2015). Indeed, with appropriate laser wavelength,
fiber diameter and source–detector separation (seeMaterials and
Methods) it has been estimated that LDF samples 1 mm3 of
tissue at a depth down to 680m (Fredriksson et al., 2009). PgE2
and PgI2 receptor antagonists were delivered by a single intracis-
ternal injection. Although this strategy has proven efficient with
little or no side effect on physiological parameters (Lecrux et al.,
2011, 2012), the precise concentration in the parenchyma is un-
known as it is governed by diffusion and largely depends on tissue
depth. We therefore tested different antagonist concentrations
(Table 4). To avoid unspecific effects of the antagonists or their
vehicle (Matsuura et al., 2009) at high concentrations, we did not
inject drugs beyond 104 M.
The EP2/EP1 antagonist AH 6809 was most effective at inhib-
iting the NVC response when delivered at 1 M (Table 4). Sur-
prisingly, at higher concentrations the AH 6809-mediated
inhibition of the NVC response was lower (Table 4). This dose-
dependent effect may be due to the lower affinity of AH 6809 for
the EP1 receptor than for the EP2 receptor (Table 3). The com-
bined antagonism of EP1/EP2 receptors obtained at higher doses
may have unmasked the vasoconstrictory effect of EP1 receptors
(Dabertrand et al., 2013) resulting in an apparent lower inhibi-
tion of the NVC response. Consistent with the results in acute
slices, AH 6809 (1 M), reduced the NVC responses to whisker
stimulation (p  0.0069, F(2,10)  8.54, repeated-measures
ANOVA; Fig. 3A,B), without altering the whisker-evoked neu-
ronal activity measured by the amplitude of the LFPs (p 
0.1453, F(2,6)  2.707, repeated-measures ANOVA; Fig. 3C),
blood gases or blood pressure (Table 5). Similarly L 161–982 (100
M; Table 4) significantly reduced the hemodynamic response
(p  0.0112, F(2,6)  10.43, repeated-measures ANOVA; Fig.
3A,B) without altering LFPs (p  0.8856, F(2,6)  0.1240,
repeated-measures ANOVA; Fig. 3C) or physiological parame-
ters (Table 5). In contrast with ex vivo observations, IP receptor
blockade with CAY 10441, even when delivered at high concen-
trations (100 M; Table 4), had no or virtually no effect on the
evoked NVC (p  0.4560, F(2,8)  0.87, repeated-measures
ANOVA; Fig. 3A,B) and electrophysiological (p 0.1412, F(2,4)
 3.323, repeated-measures ANOVA; Fig. 3C) responses, or
physiological parameters (Table 5). In line with our ex vivo data
on vascular reactivity (Fig. 1) and prostaglandin analysis (Fig. 2),
these in vivo observations indicate that COX-2-derived PgE2 act-
ing on EP2 and EP4 receptors is the main vasodilatory prosta-
glandin involved in NVC responses to sensory stimulations.
Pyramidal cells are the main cell type constitutively
expressing COX-2
To identify the cellular sources of PgE2 in NVC, we next examined
the cellular distribution of COX-2 in the different cellular elements
of theneuro-glio-vascularunit.AlthoughtheNVCresponse initiates
in layer IV of the somatosensory cortex (Silva and Koretsky, 2002;
Figure 5. Sensitivity of RT-mPCR protocols. Total cortical RNAs (500 pg) were subjected to
RT-PCR protocols designed for themolecular characterization of perivascular astrocytes (A) and
cortical neurons (B). The PCR products were resolved in separate lanes by agarose gel electro-
phoresis inparallelwith
x174digestedbyHaeIII asmolecularweightmarker and stainedwith
ethidium bromide. The amplified fragments corresponding to astrocytic (A, left) and neuronal
(B, top)molecularmarkers, aswell as PgE2 and PgI2 synthesizing enzymes (A, right,B, bottom)
had the size predicted by their mRNA sequence (Table 2).
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Tian et al., 2010; Filosa et al., 2015) we fo-
cused on layers I-IV in which COX-2 cells
predominates across the different cortical
areas (Breder et al., 1995). Consistently,
COX-2 immunolabeling obtained from 7
different rats was particularly abundant in
layer II–III (Fig. 4). It mainly consisted in
cytoplasmic staining and was virtually ab-
sent from the vascular bed stainedwith LEA
(Fig. 4A) or frommicroglia immunostained
for Iba-1 (Fig. 4B). Similarly, very few
S100-immunolabeled astrocytes were
COX-2-immunopositive (2.1 0.9%, n
3199 S100-positive cells from 4 rats;
Fig. 4C). In contrast, most COX-2-
immunoreactive cells displayed a nucleus
positive for Satb2 (Fig. 4D), a transcription
factor of pyramidal cells (S. Lee et al., 2010).
COX-2 cells accounted for 27.7  2.6% of
Satb2 neurons (n  6175 Satb2-positive
cells from 4 rats). This suggests that pyrami-
dal neurons, over astrocytes, microglia, and
endothelial cells, are theprimarycell typecon-
stitutively expressing COX-2. Nonetheless it
remains unclear whether COX-2-derived va-
sodilatory prostaglandins are directly pro-
duced by pyramidal neurons or if their
synthesis is transcellular, as suggested for 20-
hydroxyeicosatetraenoic acid (Mulligan and
MacVicar, 2004; Attwell et al., 2010), another
arachidonic acid derivative.
Astrocytes have the capability to
produce PgE2 essentially derived from
COX-1 activity
To determine the capacity of astrocytes
and neurons to produce PgE2 and PgI2
from arachidonic acid we assessed at the
single-cell level the cellular distribution of
PgE2 and PgI2 synthesizing enzymes in-
cluding the rate limiting and the terminal
synthesizing enzymes in young rats. Two
scRT-PCR protocols were respectively de-
signed for astrocyte and neuron charac-
terizations. The efficiency of the protocols
was tested on 500 pg of total RNApurified
Figure 6. Characterization of prostaglandin producing cells.A, Vital staining of a perivascular astrocytewith SR101.Wide-field
fluorescence image of the SR101-labeled cortical astrocyte (left) showing an intensely labeled cell body (arrow) sending a process
(arrowhead) onto a diving arteriole (*). Corresponding field-of-view observed under IR-DGC illumination (middle) and superim-
position of the two images (right). Pial surface is upward. Scale bar, 10m. B, Electrophysiological characterization in voltage-
clampmode of the astrocyte shown in A. Note the linear I/V curve, the low input resistance (slope) and the hyperpolarized resting
membrane potential (0 nA intercept) characteristic of passive astrocytes. The inset illustrates current responses evoked by voltage
steps (from180 to 40mV, 20mV increments) used to determine the I/V curve at steady-state. C, scRT-PCR analysis of the same
astrocyte (A, B) revealing expression of GFAP, S100, COX-1, and cPGES. D, Voltage responses induced by injection of current
pulses in a layer II–III pyramidal cell (bottom traces). Inset, IR-DGC image of the recorded cell, pial surface is upward (scale bar, 10
m). In response to just-above-threshold current pulse, this neuron fired action potentials with a long lasting biphasic AHP and
little frequency adaptation (middle trace). Near saturation, it showed the typical firing of a regular spiking neuron with marked
4
frequency adaptation and spike amplitude accommodation
(upper trace). E, The pyramidal cell shown in D expressed
vGluT1, CCK, COX-1, COX-2, and cPGES. F, Voltage responses
inducedby injectionof currentpulses in a fusiform interneuron
(bottom traces). Inset, IR-DGC image of the recorded interneu-
ron, pial surface is upward (scale bar, 10m). Note the high
input resistance of the cell observed at hyperpolarizing current
pulses (middle traces). In response to just-above-threshold
current pulse, this interneuron fired a first action potential
with a monophasic AHP followed by action potentials with
complex AHP. Near saturation, this neuron showed the firing
of an adapting-VIP interneuron with marked frequency adap-
tation and spike amplitude accommodation (upper trace). G,
This interneuron expressed vGluT1, GAD65, GAD67, CR, VIP,
CCK, COX-2, and cPGES.
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from rat cerebral cortex. Figure 5 shows that for each protocol the
sizes of all PCR-generated fragments were as predicted by the
mRNA sequences (Table 2) and confirms the sensitivity of
the scRT-PCR procedures (Cauli et al., 1997).
To facilitate astrocytes identification, slices were vitally stained
with SR101 (n 35 cells) or TxRed (n 9 cells), two related fluo-
rescentdyesof cortical astrocytes (Nimmerjahnet al., 2004). Labeled
cells were selected in the vicinity of an arteriole (Fig. 6A) and at the
border of layers I and II which contain a high density of astrocytes
(McCaslin et al., 2011) and thehighest astrocyticmolecular diversity
(Zeisel et al., 2015).Cellswere also selectedaccording to thepresence
of a prominent perivascular process (Fig. 6A) or a cell body directly
apposed to an arteriole (n 6 cells). In line with their glial identity
(Zhou et al., 2006), labeled cells exhibited small somata (Fig. 6A;
Table 6).Whole-cell recordings revealed a linear I/V curve (Fig. 6B),
a hyperpolarized membrane potential (87.9  1.3 mV), a low
input resistance (46.7 7.7M) and an inability to generate action
potentials, which are all characteristics of mature cortical astrocytes
(Zhou et al., 2006; Houades et al., 2008). The molecular analysis of
these cells revealed the expressionof at least one of the two astrocytic
markers; GFAP and S100 (Fig. 6C). Consistent with a low level of
GFAP in quiescent cortical astrocytes (Wilhelmsson et al., 2006;
Houades et al., 2008), GFAP was detected in one-half of the astro-
cytes, whereas S100was expressed inmost astrocytes (98%,n 43
of 44 cells).
As previously observed (Takano et al., 2006; Lecrux et al.,
2011), COX-1 was detected in a subpopulation of perivascular
astrocytes (20%, n 9 of 44 cells; Figs. 6C,7). In agreement with
our immunohistochemical observations (Fig. 4C), a minority of
S100-positive astrocytes expressed COX-2 (5%, n  2 of 44
cells; Fig. 7). The PGES isoform, mPGES1, was never observed
(Figs. 6C, 7B). In contrast, mPGES2 and cPGESwere respectively
detected in 5% (n 2) and 32% (n 14) of the astrocytes (Figs.
6C, 7B). PGIS was detected in 8 cells (18%; Fig. 7A,C) and was
systematically coexpressed with cPGES. Interestingly expression
of cPGES (89%, n  8 of 9 cells, p  0.0001, Fisher’s exact test)
and PGIS (44%, n 4 of 9 cells, p 0.0422, Fisher’s exact test)
was enriched in COX-1-positive astrocytes. These data confirm
the ability of perivascular astrocytes to synthesize COX-1-derived
PgE2 (Takano et al., 2006; Gordon et al., 2008) and PgI2 to a lesser
extent.
Pyramidal cells are the main cell type equipped for COX-2-
derived PgE2 biosynthesis
We next characterized layer II–III neurons to confirm at the
mRNA level our immunohistochemical observations (Fig. 4D)
and further determine the expression profile of PgE2 and PgI2
synthesizing enzymes. Pyramidal cells were chosen on the basis of
a prominent apical dendrite extending from a large triangular
soma (n 24 cells; Fig. 6D, inset; Table 6). In contrast, collected
interneurons (n 66 cells) displayed a round (n 4 cells), ovoid
(n  16 cells), or fusiform soma (n  46 cells; Fig. 6F, inset).
Whole-cell current-clamp recordings revealed a resting mem-
brane potential more hyperpolarized in pyramidal cells than in
interneurons (Fig. 6D,F; Table 7). Pyramidal cells fired larger
and wider action potentials than interneurons (Fig. 6D,F; Table
8). They also discharged at a lower-frequency (Fig. 6D,F; Table
9). This confirms the regular spiking phenotype of pyramidal
cells (McCormick et al., 1985; Cauli et al., 2000; Andjelic et al.,
2009; Karagiannis et al., 2009). Consistently, the molecular anal-
ysis of pyramidal cells revealed expression of the vesicular gluta-
mate transporter, vGluT1 (Fig. 6E) but none of the two GABA
synthesizing enzymes. CCK (Fig. 6E) and, to a lesser extent, CB
but not the other interneuron markers (Table 10), were fre-
quently observed in pyramidal cells (Cauli et al., 2000; Andjelic et
al., 2009; Karagiannis et al., 2009). In contrast, interneurons ex-
pressed at least one of the twoGADs and frequently the interneu-
ron markers (Fig. 6G; Table 10), particularly CR, NPY, or VIP.
These electrophysiological and molecular data confirm the glu-
tamatergic and theGABAergic phenotypes of pyramidal cells and
interneurons, respectively.
COX-1 was observed in 38% (n  9 of 24; Fig. 6E) and 27%
(n 18 of 66) of pyramidal cells and interneurons, respectively,
and COX-2 in 33% of pyramidal cells (n 8 of 24 cells; Figs. 6E,
7A,C) but only in 8% of interneurons (n 5 of 66 cells; Figs. 6G,
7A,C). Coexpression of both COX isoforms occurred in 17% of
pyramidal cells (Fig. 6E) and in 5% of interneurons. Similar to
astrocytes, mPGES1 was never detected in neurons (Figs. 6E,G,
7B). In contradistinction, mPGES2 and cPGES were respectively
detected in 29 (n 7 of 24 cells) and 75% (n 18 of 24 cells; Figs.
6E, 7B) of pyramidal cells and in 26 (n 17 of 66 cells) and 53%
(n 35 of 66 cells) of interneurons (Figs. 6G, 7B). Interestingly,
expression of at least one terminal PgE2 synthesizing enzyme was
observed in all COX-1- or COX-2-positive pyramidal cells (Figs.
6E, 7C), and in a majority of interneurons positive for COX-1
(94%, n 17 of 18 cells) or COX-2 (80%, n 4 of 5 cells; Figs.
6G, 7C). PGIS was expressed in 25% of pyramidal cells (n 6 of
24 cells, Fig. 7A,C) and only in 11% of interneurons (n 7 of 66
cells; Fig. 7A,C). These data indicate that subpopulations of cor-
tical neurons can synthesize PgE2 and, to a lesser extent, PgI2.
The occurrence of COX-1was similar in astrocytes, pyramidal
cells, and interneurons (astrocytes vs pyramidal cells, p 0.1563,
astrocytes vs interneurons, p  0.5006; pyramidal cells vs in-
terneurons, p  0.4364, Fisher’s exact tests; Fig. 7A,C). In con-
Table 6. Somatic properties of different cortical cells
Astrocytes (n 44) Pyramidal cells (n 24) Interneurons (n 66)
Layer 1.2 0.1 2.4 0.1 2.3 0.1
U(44,24) 46.5 U(24,66) 748.5 U(44,66) 194
p 8.1013 p 0.693357 p 4.1018
Astr Pyr, Int
Major axis (m) 18.5 0.9 30.2 2.0 23.9 0.8
U(44,24) 140 U(24,66) 450 U(44,66) 800
p 9.109 p 0.001533 p 0.00005
Astr Int Pyr
Minor axis (m) 7.9 0.3 14.4 0.7 10.3 0.2
U(44,24) 50 U(24,66) 197 U(44,66) 443
p 2.1012 p 4.109 p 6.1011
Astr Int Pyr
Elongation 2.4 0.1 2.1 0.1 2.3 0.1
U(44,24) 443 U(24,66) 620 U(44,66) 1432
p 0.28041 p 0.118109 p 0.9057
n.s.
Area (m2) 68.6 3.3 208.5 13.6 155.2 5.8
U(44,24) 2 U(24,66) 373,5 U(44,66) 47
p 4.1018 p 0.000083 p 1.1025
Astr Int Pyr
Perimeter (m) 47.5 2.3 76.5 5.1 56.3 1.7
U(44,24) 155 U(24,66) 359 U(44,66) 964
p 4.107 p 0.000045 p 0.002692
Astr Int. Pyr
Roundness 2.68 0.16 2.27 0.18 1.65 0.06
U(44,24) 420 U(24,66) 406 U(44,66) 555
p 0.168911 p 0.000315 p 1.108
Int Pyr, Astr
n, Number of cells; Astr, astrocytes; Pyr, pyramidal cells; Int, interneurons. Mann–Whitney U tests and correspond-
ing exact p values. and indicate significantly smaller with p 0.01 and0.001, respectively, with
Bonferroni correction for multiple comparisons; n.s., not statistically significant.
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trast, our immunocytochemical (Fig. 4D) and scRT-PCR data
showed that pyramidal neurons were the main cell type constitu-
tively expressing COX-2 (astrocytes vs pyramidal cells, p 
0.0026, astrocytes vs interneurons, p 0.7000; pyramidal cells vs
interneurons, p 0.0046; Fisher’s exact tests; Fig. 7A,C). Expres-
sion of at least one PGES was more frequent in neurons than in
astrocytes (astrocytes vs pyramidal cells, p 0.0001; astrocytes vs
interneurons, p  0.0018; pyramidal cells vs interneurons, p 
0.1221; Fisher’s exact tests; Fig. 7A,C). cPGES was the main iso-
form in the three cell types and was most frequent in neurons
and, particularly, in pyramidal cells (astrocytes vs pyramidal cells,
p  0.0009; astrocytes vs interneurons, p  0.0327; pyramidal
cells vs interneurons, p  0.0894; Fisher’s exact tests; Fig. 7B).
Expression mPGES2 was infrequent in neurons and very rare in
astrocytes (astrocytes vs pyramidal cells, p 0.0073; astrocytes vs
interneurons, p  0.0041; pyramidal cells vs interneurons, p 
0.7904; Fisher’s exact tests; Fig. 7B). PGIS was similarly rare in
neurons and astrocytes (astrocytes vs pyramidal cells, p 0.5415;
astrocytes vs interneurons, p  0.2717; pyramidal cells vs in-
terneurons, p  0.1000; Fisher’s exact tests; Fig. 7A,C). Consis-
tent with prostaglandin analysis (Fig. 2), these data indicate that
perivascular astrocytes and cortical neurons are better equipped
to produce PgE2 than PgI2. They also suggest that pyramidal neu-
rons are the main source of PgE2-derived from COX-2 activity.
Consistent with a neuronal origin of PgE2 in NVC, NMDA-
induced vasodilations were dramatically reduced by blockade of
action potentials with TTX (5 M, n  8 arterioles, maximal
dilation 20.8 3.9%, p 0.00002,U(16,8) 3, magnitude 9.0
2.2 103.%.s, p 0.00037, U(16,8) 10; Mann–Whitney U tests;
Fig. 1) indicating that neuronal activity is required for these
responses.
Optogenetic stimulation of pyramidal cells induces COX-2-
dependent hyperemic responses
Similar to LDF, it has been reported that 95% of the laser-speckle
contrast imaging signal comes from the top 700 m of tissue
(Davis et al., 2014). To evaluate functionally the capability of
pyramidal cells to release vasodilatory prostaglandins in vivo, we
combined direct optogenetic stimulation of channelrhodopsin-2
(ChR-2)-expressing neurons with laser speckle contrast imaging
of cerebral blood flow (Scott and Murphy, 2012). Similarly to
rats, mice exhibit a COX-2-dependent NVC response to sensory
stimulation (Niwa et al., 2000; Bakalova et al., 2002; Stefanovic et
al., 2006; Lecrux et al., 2011). We therefore took advantage of
available Cre driver lines to obtain an expression of ChR2 in
pyramidal cells. Efficient expression of ChR-2 was obtained by
crossing Emx1-Cre mice with Ai32 mice which permits a condi-
tional expression of ChR2 and a robust photoexcitability of py-
ramidal cells (Madisen et al., 2012). Photoexcitation at 473 nm
(100 Hz, 5 ms, 3 mW) of Emx1-Cre;Ai32 mice (n  5 mice)
Figure 7. Expression profiles of the PgE2 and PgI2 synthesizing enzymes. A, Histograms depicting the occurrence of prostanoid synthesizing enzymes in identified cell types. PGES denotes
expression of mPGES1, 2, and/or cPGES. Layer II–III cortical pyramidal neurons (n 24 cells, black) express much more frequently COX-2, than perivascular astrocytes (n 44 cells, red) and
interneurons (n 66 cells, white). B, Occurrence of the three PGES isoforms in identified cell types. mPGES1 is not detected in any cell types. mPGES2 is more frequently observed in pyramidal
neurons and interneurons than in astrocytes. cPGES is detected in the three cell types butmore frequently in pyramidal cells than in astrocytes. *, **, and *** statistically significant with p 0.05,
p0.01, and p0.001 respectively. C, Coexpression of prostanoid synthesizing enzymes in identified cell types. The occurrence of cells positive for an enzyme is proportional to the size of the box
in a given cell type. Coexpression of PGES (green) and PGIS (blue) with COX-1 (top, purple) and with COX-2 (bottom, red) in astrocytes (S100 and/or GFAP-positive; left), pyramidal cells
(vGluT1-positive; middle) and interneurons (GAD65- and/or 67-positive; right).
Table 7. Subthreshold properties of different neuronal populations
Pyramidal cells (n 24) Interneurons (n 66)
Resting potential, mV 69.7 1.8 59.8 0.8
U(24,66) 286.5 p 0.000001
Pyr Int
Input resistance, M 277 30 526 29
U(24,66) 250 p 1.10
7
Pyr Int
Time constant, ms 32.2 2.6 32.2 2.1
U(24,66) 728 p 0.564733
n.s.
Membrane capacitance, pF 122.4 5.8 67.5 4.5
U(24,66) 133 p 2.10
11
Int. Pyr.
Sag index, % 7.1 1.4 9.6 1.1
U(24,66) 669 p 0.265639
n.s.
Pyr, Pyramidal cells; Int, interneurons, n, number of cells; Mann–Whitney U tests and corresponding exact p values;
 indicates significantly smaller with p 0.001; n.s., not statistically significant.
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elicited a rapid and transient increase in cerebral blood flow (Fig.
8; magnitude 118.3  24.2%.s, maximal change 27.7  3.5%)
that was not observed with Thy1-YFP mice that do not express
ChR2 (n 4mice,magnitude 2.9 3.2%.s, p 0.01587,U(5,4)
0; maximal change 5.6 1.2%, p 0.01587, U(5,4) 0, Mann–
WhitneyU tests; Fig. 8B–D). Consistent with the release of COX-
2-derived PgE2, laser speckle contrast changes evoked by
photoexcitation of Emx1-Cre;Ai32 pyramidal cells were reduced
by application of the COX-2 inhibitor NS 398 (100 M, Magni-
tude 55.9  12.4%.s, p  0.0226, t(4)  3.6064, paired t test,
maximal change 16.0 3.7%, p 0.0226, t(4) 3.6080, paired t
test; Fig. 8B–D). These optogenetic results show that direct acti-
vation of pyramidal cells is sufficient to release COX-2-derived
vasodilatory prostaglandins.
Table 8. Action potential waveform properties of different neuronal populations
Pyramidal cells
(n 24)
Interneurons
(n 66)
1 st spike amplitude, mV 96.6 2.3 89.2 1.4
U(24,66) 476,5 p 0.00354
Int Pyr
2 nd spike amplitude, mV 95.0 2.3 85.2 1.5
U(24,66) 369 p 0.00007
Int Pyr
1 st spike duration, ms 1.3 0.1 0.7 0.1
U(24,66) 231 p 4.10
8
Int Pyr
2 nd spike duration, ms 1.3 0.1 0.7 0.0
U(24,66) 223 p 3.10
8
Int Pyr
Amplitude reduction, % 1.6 0.3 4.4 0.8
U(24,66) 553 p 0.02888
Pyr Int
Duration increase, % 0.7 0.3 0.8 1.9
U(24,66) 628 p 0.13646
n.s.
1 st spike, 1 st component AHP, mV 5.9 0.6 15.2 0.6
U(24,66) 52 p 8.10
16
Int Pyr
1 st spike, 1 st AHP component latency, ms 7.0 0.6 3.8 0.2
U(24,66) 240 p 8.10
8
Int Pyr
1 st spike, 2 nd component AHP, mV 12.9 0.6 7.6 0.9
U(24,66) 443 p 0.00121
Pyr Int
1 st spike, 2 nd AHP component latency, ms 50.2 4.5 15.6 2.1
U(24,66) 155 p 1.10
10
Int Pyr
1 st spike, ADP, mV 0.0 0.0 1.9 0.3
U(24,66) 444 p 0.00125
Pyr Int
1 st spike, ADP latency, ms 0.0 0.0 4.4 0.7
U(24,66) 444 p 0.00125
Pyr Int
2 nd spike, 1 st component AHP, mV 6.5 0.7 15.6 0.6
U(24,66) 82 p 6.10
14
Int Pyr
2 nd spike, 1 st AHP component latency, ms 9.3 1.6 3.8 0.3
U(24,66) 199 p 5.10
9
Int Pyr
2 nd spike, 2 nd component AHP, mV 13.5 0.8 9.5 0.9
U(24,66) 494 p 0.00608
Int Pyr
2 nd spike, 2 nd AHP component latency, ms 55.6 5.9 18.0 1.9
U(24,66) 172 p 6.10
10
Int Pyr
2 nd spike, ADP, mV 0.0 0.0 1.9 0.3
U(24,66) 432 p 0.00082
Pyr Int
2 nd spike, ADP latency, ms 0.0 0.0 2.9 0.4
U(24,66) 432 p 0.00082
Pyr Int
Pyr, Pyramidal cells; Int, interneurons; n, number of cells; Mann–Whitney U tests and corresponding exact p values;
, and indicate significantly smaller with p 0.05, 0.01, and0.001, respectively; n.s., not
statistically significant.
Table 9. Firing properties of different neuronal populations
Pyramidal cells (n 24) Interneurons (n 66)
Amplitude accommodation, mV 12.0 1.3 4.2 0.5
U(24,66) 242 p 9.10
8
Int Pyr
Amplitude of early adaptation, Hz 95.1 7.8 77.5 5.4
U(24,66) 551 p 0.02753
Int Pyr
Time constant of early adaptation, ms 15.4 1.5 25.2 2.1
U(24,66) 398 p 0.00023
Pyr Int
Maximal steady-state frequency, Hz 45.6 2.8 92.0 7.5
U(24,66) 315 p 0.00001
Pyr Int
Late adaptation, Hz/s 24.6 1.9 189.3 151.0
U(24,66) 633 p 0.14899
n.s.
Pyr, Pyramidal cells; Int, interneurons; n, number of cells; Mann–WhitneyU tests and corresponding exact p values;
 and  indicate significantly smaller with p  0.05 and 0.001, respectively; n.s., not statistically
significant.
Table 10. Occurrence of molecular markers in different neuronal populations
Pyramidal cells, %
(n 24)
Interneurons, %
(n 66)
vGluT1 100 45
p 0.0000
Int Pyr
GAD 0 100
p 0.0000
Pyr Int
NOS-1 0 9
p 0.1873
n.s.
CB 46 26
p 0.0781
n.s.
PV 21 21
p 1.0000
n.s.
CR 0 27
p 0.0024
Pyr Int
NPY 0 20
p 0.0171
Pyr Int.
VIP 0 48
p 0.0000
Pyr. Int
SOM 25 29
p 0.7959
n.s.
CCK 79 47
p 0.0082
Int Pyr
Pyr, Pyramidal cells; Int, interneurons; n, number of cells; Fisher’s exact test p values;, and indicate
significantly smaller with p 0.05,0.01, and0.001, respectively; n.s., not statistically significan.
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Discussion
Here we deciphered the molecular and cellular mechanisms re-
sponsible for the biosynthesis and activity of vasodilatory prosta-
glandins involved in NVC (Fig. 9). We identified in slices the
rate-limiting enzyme involved in this pathway by showing that
COX-2, but also to a lesser extent COX-1, metabolites mediate
NMDA-induced vasodilations. Further, we identified PgE2 as the
main vasodilatory prostaglandins by demonstrating ex vivo and
in vivo the implication of its EP2 and EP4 receptors and by show-
ing its release ex vivo using LC-ESI-MS/MS.We found that pyra-
midal cells are the main cell type equipped for PgE2 synthesis
derived from COX-2 activity. Moreover we showed that in-
creased activity of these neurons through direct optogenetic
stimulation evoked COX-2-dependent NVC responses, hence
demonstrating a key role for PgE2-derived from pyramidal cells
in NVC responses.
Cellular distribution of PgE2 and PgI2 synthesizing enzymes
Our data showing COX-1 expression in various cell types are
supported by previous observations demonstrating its localiza-
tion in microglia, astrocytes, neurons and endothelial cells (Ta-
kano et al., 2006; Cahoy et al., 2008; Gordon et al., 2008; Tang and
Vanhoutte, 2008; Tanaka et al., 2009; Anrather et al., 2011; Lec-
rux et al., 2011). In contrast, we observed by immunohistochem-
istry and scRT-PCR that COX-2 is largely restricted to pyramidal
neurons, rarely in astrocytes and interneurons, and virtually ab-
sent in microglial cells and the vascular bed (Yamagata et al.,
1993; Breder et al., 1995; Kaufmann et al., 1996;Wang et al., 2005;
Takano et al., 2006; Cahoy et al., 2008; Gordon et al., 2008; An-
rather et al., 2011; Lecrux et al., 2011). Regarding the terminal
PgE2 synthesizing enzymes, cPGES was observed in all cell types
investigated (Vazquez-Tello et al., 2004; Sang et al., 2005; Cahoy
et al., 2008),mPGES2was essentially detected in neurons (Sang et
Figure 8. Optogenetic stimulations of pyramidal cells evoke COX-2-dependent hyperemic responses. A, Variance filtered speckle contrast image. Darker tones represent higher velocity blood
flow.Montageof fractional change in speckle contrast images fromcortical optogenetic stimulationof anEmx1-Cre;Ai32mouse.B, Optogenetically evoked increases inblood flow, the scaled inverse
square of speckle contrast, before (black trace) and after application of NS 398 (red trace; n 5mice). Blue light excitation (473 nm) in Thy1-YFPmice (yellow; n 4mice) does note evoke increase
in blood flow. The SEM envelopes themean traces. C,D, Effects of photostimulation onmagnitude (C) andmaximal changes (D) of blood flow in Thy1-YFP and Emx1-Cre;Ai32mice before and after
NS 398 application. Dots represent individual neurovascular responses. Horizontal bars and error bars correspond to the mean SEM. *Statistically different from Emx1-Cre;Ai32 mice under
baseline condition with p 0.05.
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al., 2005; Cahoy et al., 2008), whereas
mPGES1 was virtually absent from neu-
rons and astrocytes (Ikeda-Matsuo et al.,
2006; Cahoy et al., 2008). We also con-
firmed a rather infrequent PGIS expres-
sion (Mehl et al., 1999; Cahoy et al., 2008).
Importantly, we disclosed that COX-2-
positive pyramidal cells systematically ex-
press a cPGES and/or mPGES2 to a lesser
extent. This indicates that under homeo-
static conditions COX-2-derived PgE2 is
essentially produced by pyramidal cells.
Origins of vasodilatory prostaglandins
in NVC
Perivascular astrocytes can release COX-
1-, but not COX-2-derived, vasodilatory
prostaglandins following activation of
group Imetabotropic glutamate receptors
(Zonta et al., 2003; Takano et al., 2006;
Gordon et al., 2008). However, the re-
cruitment of this pathway during sensory
stimulation is unlikely because pharma-
cological and genetic evidence showed
that such stimuli elicit COX-2, but not
COX-1,-dependent hyperemic responses
(Niwa et al., 2000, 2001; Bakalova et al.,
2002; Stefanovic et al., 2006; Lecrux et al.,
2011). Furthermore, the recruitment of
astrocytes by group I metabotropic glutamate receptors has been
recently questioned (Calcinaghi et al., 2011; Nizar et al., 2013;
Sun et al., 2013; Bonder and McCarthy, 2014; Jego et al., 2014).
This suggests that under normal conditions sensory stimulations
do not substantially recruit vasodilatory prostaglandins pro-
duced by astrocytes.
We found that NMDA-induced vasodilations were almost
completely abolished by COX-2 inhibition, suggesting that the
NMDA-dependent fraction of the NVC response is essentially
mediated by vasodilatory prostaglandins. Our results indicating
that COX-2-derived PgE2 released during sensory stimulation
has a pyramidal origin are supported further by optogenetic ob-
servations showing that the selective photostimulation of
CaMKII pyramidal cells, which extensively coexpress COX-2
(Kaufmann et al., 1996), evoked a hemodynamic response (J. H.
Lee et al., 2010; Ji et al., 2012). In addition, the NVC responses
induced by the photostimulation of pyramidal neurons, but not
by sensory stimulation, are virtually insensitive to ionotropic glu-
tamate receptors blockade (Scott and Murphy, 2012). This fur-
ther points to release of vasodilatory messengers by pyramidal
cells. Since the NVC involves numerous vasoactive messengers
(Iadecola, 2004; Leithner et al., 2010; Liu et al., 2012), it is likely
that the optogenetic photostimulation of pyramidal cells recruits
indirectly other vasoactive messengers. Consistently, a substan-
tial fraction of the NVC response to sensory stimulation is insen-
sitive to COX-2 inhibition (Niwa et al., 2000; Bakalova et al.,
2002; Stefanovic et al., 2006; Lecrux et al., 2011) and PgE2 recep-
tor antagonism (present study). Interestingly, COX-2 has been
described in dendrites, spines or axon terminals (Kaufmann et
al., 1996; Wang et al., 2005), suggesting that pyramidal cells can
remotely release PgE2.
We found that the initial phase ofNMDA-induced vasodilations
was also COX-1-dependent. The cellular origin of COX-1-derived
prostaglandins released byNMDA remains undetermined given the
large cellular distribution of COX-1 (see above) and the widespread
expression of NMDA receptors in various neuronal types (Cauli et
al., 2000), but also in some astrocytes, microglial and endothelial
cells (Lalo et al., 2006; Kaindl et al., 2012; LeMaistre et al., 2012).
Microglia, a major cell type expressing COX-1, can release PgE2
upon NMDA stimulation, but secondary to neuronal ATP release
(Anrather et al., 2011) making unlikely their contribution to the
early NVC response. The expression of COX-1 in neurons and as-
trocytes suggests that these cell types might be responsible for the
early NVC response. Finally, given that endothelial cells play a key
role in fast hemodynamics (Chen et al., 2014), they might also con-
tribute to the early NVC response.
Release of prostaglandins
Consistentwith in vivodata (Lazarewicz and Salin´ska, 1995; Pepi-
celli et al., 2005; Anrather et al., 2011) we observed a COX-1 and
COX-2-dependent release of PgE2 and 6-keto PgF1. The level of
PgE2 release byNMDA is approximately one-half that foundwith
mGluR1/5 agonists (Gordon et al., 2008), suggesting that they are
more efficient than NMDA at inducing PgE2 release. This is con-
sistent with widespread expression of mGluR1/5 in astrocytes
and neurons (Porter and McCarthy, 1996; Cauli et al., 2000).
However, number of slices and duration of incubation were not
described (Gordon et al., 2008) making a direct comparison dif-
ficult. Furthermore, due to cross-reactivity among the different
prostaglandins, the content in PgE2may have been overestimated
by using immunoassay (Schmidt et al., 2005). Interestingly, in
line with in vivo observations (Lazarewicz et al., 2000), using
LC-ESI-MS/MS we found that up to 396 141 pg/ml PgD2 was
released by NMDA, a prostaglandin structurally similar to PgE2.
The dynamics of the NMDA-dependent PgE2 and 6-keto
PgF1 (Fig. 2) are overall compatible with the kinetics NMDA-
induced vasodilations (Fig. 1). However a direct comparison is
difficult given the differentmode ofNMDAdelivery andwashout
between supernatant analysis and vascular reactivity (Mishra et
Figure 9. Biosynthesis and vasodilatory effects of PgE2 and PgI2. Increased intracellular calcium activates phospholipase A2
(PLA2). Arachidonic acid (AA) is released from membrane phospholipids (MPL) by PLA2 and metabolized by COX-1 or COX-2 to
produce the intermediary prostaglandinH2 (PgH2). PgE2 andPgI2 are, respectively, synthesized fromPgH2 by PGES andPGIS. Upon
binding and action on type 2 or 4 PgE2 (EP2/4) or PgI2 (IP) receptors these two prostaglandins relax smoothmuscle cells (SMCs) or
pericytes and dilate blood vessels. AA can be also metabolized by a cytochrome P450-epoxygenase (Cyp450) to produce 14,15-
epoxyeicosatrienoic acid (14,15 EET) which induces EP2-dependent vasodilation. EC, Endothelial cell. SC 560 and NS 398 are
selective COX-1 and COX-2 inhibitors respectively. Indomethacin (Indo) is a nonselective COX-1/2 inhibitor. AH 6809, L161-982,
and CAY 10441 are EP2, EP4, and IP antagonists, respectively.
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al., 2014). The sustained vasodilation after NMDA washout is
reminiscent of an intracellular Ca2 increase after a prolonged
exposure of NMDA, involving an initial increase via NMDA re-
ceptors followed by a secondary activation of other Ca2-
permeable channels including transient receptor potential
channels (Olah et al., 2009) and/or voltage-gated Ca2 channels
(Oda et al., 2014). Recruitment of extrasynapticNMDAreceptors
are likely to be responsible for this secondary Ca2 increase (Oda
et al., 2014) and overproduction of PgE2 (Stark and Bazan, 2011).
Whether or not these different initial entry points are specifically
coupled with COX-1 and/or COX-2 remains to be determined.
Prostaglandin receptors in NVC
The prostaglandin receptors EP2, EP4, and IP are expressed in
cerebrovascular smooth muscle cells and pericytes (Myren et al.,
2010, 2011; Dabertrand et al., 2013; Hall et al., 2014). We ob-
served an impairment of the NVC responses by the EP2 and EP4
antagonists both ex vivo and in vivo. These data suggesting an
involvement of PgE2 are consistent with recent observations
showing a recruitment of EP4 receptors in cerebral vasodilation
evoked by glutamate (Hall et al., 2014). Antagonism of both EP2
and EP4 receptors reduced the maximal amplitude of NMDA-
induced vasodilation, but theirmagnitude were only impaired by
the EP2 antagonist, indicating that EP2 receptors may have a
longer lasting vasodilatory effect than EP4 receptors. This is con-
sistent with the reported agonist-induced internalization of EP4
but not EP2 receptor (Desai et al., 2000). This further suggests
that EP2 receptor would be the major vasodilatory PgE2 receptor
activated during a sustained hyperemic response. Because 14,15-
EET can induce vasodilation by acting on EP2 receptors (Yang et
al., 2010), the AH 6809-sensitive vasodilation could be also ex-
plained by the release of 14,15-EET from astrocytes (Alkayed et
al., 1996, 1997; Fig. 9). Although the IP antagonist impaired
NMDA-induced vasodilations in slices, it did not alter the hyper-
emic response to sensory stimulation. This difference between ex
vivo and in vivo NVC responses is probably because bath appli-
cation of NMDA recruits more massively NMDA receptors than
sensory stimuli, resulting in enhanced PgI2 biosynthesis and re-
lease. In addition, the levels of 6-keto PgF1 released in slices are
very low; it is therefore likely that the production of PgI2 induced
by sensory stimulation in vivo is negligible.
Conclusion
Using different multidisciplinary approaches we demonstrate
that pyramidal cells produce and release COX-2-derived PgE2
inducing vasodilation and functional hyperemia via activation of
EP2 and EP4 receptors. So far most studies focused almost exclu-
sively on the role of astrocytes in NVC (Attwell et al., 2010)
thereby overlooking the possibility of a direct neurogenic control.
Our finding emphasizing the importance of neurons provides
important insights in the field of NVC and will have conse-
quences on the interpretation of functional imaging based on
hemodynamic signals widely used to map neuronal activity in
health and disease.
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